Product Name

ARX788 HER2 ADC – Oncology


ARX788 is an antibody drug conjugate (ADC) that targets HER2 over-expressing tumors including breast, gastric, colon, pancreatic and ovarian cancers. ARX788 is based on our next-generation ADC technology platform whereby a HER2 specific monoclonal antibody is site-specifically conjugated with Amberstatin269, a potent cytotoxic tubulin inhibitor. In pre-clinical models, ARX788 has demonstrated an improved efficacy and safety profile relative to currently available HER2 targeting ADCs. ARX788 has the potential to benefit a broader spectrum of HER2+ cancer patients than those that can be treated with the currently available HER2 targeted therapies and to improve outcomes for those patients that are eligible for current HER2-targeted therapies. Preclinical studies demonstrated that ARX788 is effective in controlling xenograft tumors, and safety studies in rodents and non-human primates demonstrated that ARX788 is well tolerated at doses significantly higher than the doses required to demonstrate efficacy.

Fact Sheet

Data Sheet